新辅助放化疗联合手术治疗ⅠB2~ⅡA2期子宫颈癌临床预后因素分析

doi:10.3969/j.issn.1007-3969.2016.05.013

中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (5): 427-433.doi: 10.3969/j.issn.1007-3969.2016.05.013

新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析

刘　健¹，崔艳艳²，李胜泽¹，马　玲¹，李　群¹，李玉芝¹，郭苏阳¹，刘静波¹

1. 蚌埠医学院第一附属医院妇瘤科，安徽蚌埠 233004 ；
2. 怀远县第二人民医院妇产科，安徽怀远 233400

出版日期:2016-05-30 发布日期:2016-06-23
通信作者: 刘健　E-mail：Elitelj@126.com
基金资助:
安徽省自然科学基金(KJ2015B0966Y)。

Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery

LIU Jian¹, CUI Yanyan², LI Shengze¹, MA Ling¹, LI Qun¹, LI Yuzhi¹, GUO Suyang¹, LIU Jingbo¹

1. Department of Gynecological Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China; 2. Department of Gynecology and Obstetrics, the Second People’s Hospital of Huaiyuan County, Huaiyuan 233400, Anhui Province, China

Published:2016-05-30 Online:2016-06-23
Contact: LIU Jian E-mail: Elitelj@126.com

摘要/Abstract

摘要： 背景与目的：探讨Ⅰ_B2～Ⅱ_A2期子宫颈腺癌与腺鳞癌经新辅助放化疗联合手术治疗后的生存及复发情况，并分析其预后影响因素。方法：收集蚌埠医学院第一附属医院2005年4月—2011年10月50例Ⅰ_B2～Ⅱ_A2期患者的临床病理资料。患者均接受广泛全子宫切除+盆腔淋巴结清扫术，且术前均接受1次静脉化疗，宫颈肿瘤直径大于等于6 cm，给予阴道腔内放疗1次。回顾分析患者的生存及复发情况，探讨其预后影响因素。结果：50例Ⅰ_B2～Ⅱ_A2期子宫颈腺癌和腺鳞癌患者中，随访期内死亡15例，2年和5年无进展生存率分别是80.12%和72.24%，中位无进展生存时间为68个月；2年和5年累积总生存率分别是95.38%和73.56%，中位总生存时间为80个月。单因素分析显示，盆腔淋巴结转移、宫颈间质浸润、宫旁浸润和新辅助放化疗后肿瘤最大直径缩短小于3 cm的患者预后较差(P<0.05)，而年龄、术后放化疗、淋巴管间隙受累分期、FIGO分期、是否保留卵巢和病理类型与预后无明显相关性(P>0.05)。多因素COX回归分析结果显示，盆腔淋巴结转移和放化疗后肿瘤直径缩小是宫颈腺癌和腺鳞癌的独立预后影响因素。结论：新辅助放化疗联合手术治疗提高了Ⅰ_B2～Ⅱ_A2期宫颈腺癌和腺鳞癌手术切除率，而盆腔淋巴结转移及放化疗后宫颈肿瘤最大径消退程度是宫颈腺癌和腺鳞癌的独立预后因素。

关键词: 子宫颈癌, 辅助放化疗, 子宫切除术, 预后

Abstract: Background and purpose: The aim of this study was to analyze the prognostic factors in uterine adenocarcinoma and adenosquamous carcinoma treated with a combination of neoadjuvant chemoradiotherapy and surgery. Methods: Clinicopathologic data from 50 patients with stageⅠ_B2-Ⅱ_A2 uterine cervical cancer were collected from the First Affiliated Hospital of Bengbu Medical College between Apr. 2005 and Oct. 2011. All patients underwent neoajuvant chemoradiotherapy, followed by radical hysterectomy and pelvic lymph node dissection. Before surgery, an intravenous chemotherapy was given. A particular vaginal brachytherapy was given to those with tumor diameter ≥6 cm. The survival and recurrence in patients were analyzed retrospectively to investigate the prognostic factors. Results: In 50 patients with Ⅰ_B2-Ⅱ_A2uterine adenocarcinoma and adenosquamous carcinoma, 15 died during the follow-up period. The 2-year and 5-year progression-free survival rates were 80.12% and 72.24%, respectively, and median progression-free survival was 68 months. The 2-year and 5-year overall survival rates were 95.38% and 73.56%, respectively, and median overall survival was 80 months. Univariate analysis revealed that pelvic lymph node metastasis, cervical stromal invasion, parametrial infiltration, tumor diameter reduction <3 cm and advanced stage were the prognostic factors in patients with cervical cancer (P<0.05). Age, postoperative radiochemotherapy, lymphatic clearance involvement, FIGO stage, preservation of ovary and pathologic type were not associated with prognosis (P>0.05). Multivariate Cox proportional analysis revealed that pelvic lymph node metastasis and tumor diameter reduction after radiation and chemotherapy were the independent prognostic factors in patients with cervical cancer. Conclusion: The combination of neoadjuvant chemotherapy and surgery improves the resectable rate of patients with Ⅰ_B2-Ⅱ_A2 uterine adenocarcinoma and adenosquamous carcinoma. Pelvic lymph node metastasis and tumor diameter reduction after radiation and chemotherapy are the independent prognostic factors in patients with cervical cancer.

Key words: Cervical cancer, Neoadjuvant chemotherapy, Hysterectomy, Prognosis

刘　健,崔艳艳,李胜泽,等. 新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析[J]. 中国癌症杂志, 2016, 26(5): 427-433.

LIU Jian, CUI Yanyan, LI Shengze, et al. Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery[J]. China Oncology, 2016, 26(5): 427-433.

[1]	林艺, 王策, 康勋, 康庄, 陈峰, 江波, 李文斌. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23.
[2]	马祎菲, 梁新军, 魏少忠 . 炎症与免疫指标在可切除性结直肠癌中的预后价值[J]. 中国癌症杂志, 2021, 31(9): 845-851.
[3]	方艳惠, 马彩娟, 张纯丽, 翟嘉威, 朱巧英, 刘茵, 赵喜娃. miR-496通过SFMBT1抑制子宫颈癌HeLa细胞增殖、迁移和侵袭的相关研究[J]. 中国癌症杂志, 2021, 31(8): 697-703.
[4]	龙行涛, 周琦, 王冬, 陈月梅, 金福军 . 子宫颈癌2018年FIGO新分期ⅢC期患者预后分析[J]. 中国癌症杂志, 2021, 31(8): 725-733.
[5]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[6]	高鹤丽, 徐　近, 虞先濬. 分化好的胃肠胰神经内分泌瘤G3的诊治新进展[J]. 中国癌症杂志, 2021, 31(7): 567-573.
[7]	中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南（2021年版）[J]. 中国癌症杂志, 2021, 31(6): 474-489.
[8]	巩润泽, 胡海燕. CCL2在骨肉瘤组织中的表达及其临床意义[J]. 中国癌症杂志, 2021, 31(6): 455-459.
[9]	董诗洁, 胡晓欣, 王　葳, 杨　孟, 岳　磊, 童　彤, 顾雅佳. 基于多序列MRI与多体系影像组学模型预测子宫颈癌淋巴结转移的研究[J]. 中国癌症杂志, 2021, 31(6): 460-467.
[10]	彭子珊, 孔　辉, 鲍　真, 赵红杏, 刘　鑫, 卢韶华. 83例多发肺腺癌患者的临床病理学特征分析[J]. 中国癌症杂志, 2021, 31(5): 408-418.
[11]	肖　锋, 肖静文, 邵建国, 陈丽燕, 顾春燕 . PD-1在肝细胞癌肿瘤浸润淋巴细胞中的表达及与预后的相关性[J]. 中国癌症杂志, 2021, 31(5): 419-427.
[12]	王春建 , 聂　刚 , 毛　艳 . TRIP6在乳腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2021, 31(3): 161-169.
[13]	武元元 , 王　军 , 刘勤江 , 张　明 . 甲状腺未分化癌的预后因素分析及治疗决策[J]. 中国癌症杂志, 2021, 31(3): 212-220.
[14]	杨柳松, 祝迎锋, 唐剑敏 . 上皮样胶质母细胞瘤10例报告并文献复习[J]. 中国癌症杂志, 2021, 31(2): 114-120.
[15]	丁平安, 张志栋, 杨沛刚, 林叶成, 田　园, 徐校胜, 吴　娟, 刘　颖, 郭洪海, 刘　洋, 王　冬, 檀碧波, 李　勇, 赵　群 . 胃癌脑膜转移的临床病理学特征及预后分析[J]. 中国癌症杂志, 2021, 31(2): 126-135.

新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析

Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

新辅助放化疗联合手术治疗ⅠB2~ⅡA2期子宫颈癌临床预后因素分析

Analysis of prognostic factors in patients with stage ⅠB2-ⅡA2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析

Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery